Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-4359 Alone and in Combination With Immune Checkpoint Blockade in Advanced Solid Tumors
NCT05533697Phase 2Recruiting
- Sponsor
- Moderna Inc
- Start
- Sep 2022
- Primary completion
- Feb 2032
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 7
01
Overview
A Phase 2 trial of mRNA-4359 in solid tumor, melanoma, non-small cell lung cancer (NSCLC), sponsored by Moderna Inc. Started Sep 2022; status: recruiting.
02
Drugs
mRNA-4359
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05533697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533697.